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Summary 
A subtractive analysis ofpeptides eluted from major histocompatibility complex (MHC) class I 
human histocompatibility leukocyte antigen (HLA)-A2.1 molecules purified from either hu- 
man immunodeficiency virus type-1 (HIV-1)-infected or uninfected cells was performed using 
micro high-performance liquid chromatography and mass spectrometry. Three peptides unique 
to infected cells were identified and found to derive from a single protein, human vinculin, a 
structural protein not known to be involved in viral pathogenesis. Molecular and cytofluoro- 
metric analyses revealed vinculin mRNA and vinculin protein overexpression in B and T lym- 
phocytes from HIV-l-infected individuals. Vinculin peptide-specific CTL activity was readily 
elicited from peripheral blood lymphocytes of the  majority of HLA-A2.1 +,  HIV  +  patients 
tested. Our observations suggest that atypical vinculin expression and MHC class I-mediated 
presentation of vinculin-derived peptides accompany HIV infection of lymphoid cells in vivo, 
with a resultant induction of antivinculin CTL in a significant portion of HIV  + (HLA-A2.1 +) 
individuals. 
C 
TL (CD8 +)  recognize antigenic peptides  complexed 
with MHC class I molecules on the surface of target 
cells. Cytotoxic T  cells play a crucial role in the protective 
immune response to numerous experimental models of vi- 
rus infection and disease  (1,  2).  There also  is strong evi- 
dence that HIV-l-specific CTL play a pivotal role in con- 
trolling  HIV  in  vivo.  Vigorous  HIV-l-specific  CTL 
responses have been detected in infected asymptomatic in- 
dividuals,  and  these  responses  subsequently  decline  with 
disease  progression  (3).  Furthermore,  recent studies  indi- 
cated a correlation between the presence of CTL immunity 
and the ability of some of these individuals to control virus 
spread and replication and to become long-term survivors 
of HIV infection (4-6). 
Conversely,  a  possible  role  for  virus-specific  CTL  in 
HIV-induced immunopathology has also  been postulated. 
Adoptive transfer of a HIV-specific CTL clone to an AIDS 
patient resulted in  the  selection for mutant  HIV variants 
and disease progression (7). In addition, very high viral rep- 
lication in  the presence of a potent CTL response could 
also lead to T  cell-mediated immunopathological damage, 
as observed in some model infections with noncytopathic 
viruses (8). 
The  identification  of naturally  processed,  class I-pre- 
sented peptides unique to HIV-infected cells could provide 
information regarding HIV-related epitopes and the func- 
tional role of  CTL in HIV infection and disease. To this end, 
in this study we performed a subtractive analysis of peptides 
eluted  from MHC  class  I  HLA-A2.1  molecules purified 
from either HIV-l-infected or uninfected cells by micro- 
high HPLC and mass  spectrometry (MS)k  Class  I-bound 
peptides arising as a result of HIV infection would be ex- 
pected to derive from viral proteins but might also  derive 
from endogenous (cellular) proteins. The application of  this 
very sensitive new technology allowed us  to identify the 
Contributions of F. di Marzo Veronese,  D. Amott, and V. Bamaba were 
equivalent and the order of  their names should be considered  arbitrary. 
1Abbreviations used in this paper: ESI-TMS, electrospray-ionization/triple 
quadruple mass spectrometry;  MS, mass spectometry;  m/z, charge/mass; 
RP, reverse  phase. 
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out biasing the search towards a specific gene product. 
Materials and Methods 
Cell Lines and Viruses.  The  EBV-B  lymphoblastoid cell  line 
designated AA2 is highly permissive for HIV-1 infection (9) and 
expresses HLA-A2.1. We chronically infected the AA2 cell line 
with HIV-1 strain IIIB. The cell line was tested for expression of 
HIV-1 proteins by p24 antigen capture assay and immunoprecip- 
itation  of  lysates prepared  from  metabolically  [3SS]cysteine- 
labeled cells. The antigen capture  assay was performed according 
to the instructions of a commercially available kit from Cellular 
Products (Buffalo, NY) and revealed specific release of~100 ng 
of HIV-1  p24/ml in the supernatant of the  infected cells. The 
immunoprecipitation was performed with a serum from a HIV- 
1-positive subject and unequivocally demonstrated specific and 
abundant expression  of HIV-1  proteins. Individual clones  were 
derived from the bulk-infected cells by limiting dilution and were 
monitored for viral protein expression by p24 antigen capture  as- 
say  and  by  indirect immunofluorescence. One  of the  clones, 
showing evidence of uniform and abundant viral  envelope ex- 
pression in all cells by irnmunofluorescence,  was designated AA2- 
IIIB and selected for large scale expansion. JY is an EBV-B lym- 
phoblastoid cell line also expressing HLA-A2.1. Jurkat is a T cell 
line derived from acute T  cell leukemia. Jurkat A2 was derived 
from Jurkat upon transfection  of the HLA-A2.1 gene. 
Extraction ofMHC-bound Peptides.  Each batch ofpeptides was 
the product of a cell pellet from 10 liters of cells containing  "~5 ￿ 
109 cells. Purification of MHC and elution ofpeptides was carried 
out according to  previously described  procedures  (10). Soluble 
proteins from the cell lysate were passed over GAP-A3 (irrelevant 
antibody) and BB7.2  (anti-HLA-A2.1) immunoaffinity columns. 
Peptides were eluted with 0.2N acetic acid, pH 2.7, further acid- 
ified with glacial acetic acid to pH 2.1, and collected by centrifu- 
gation through a 5-kD filter.  The resulting fractions  were con- 
centrated by vacuum centrifugation and screened by MS.  Those 
fractions that contained peptides were pooled together.  Typically, 
three preparations  from 10-liter cell suspensions  were  extracted 
and pooled for analysis. 
Reduction and Carboxyamidation of Cys-containing Peptides.  Re- 
duction of disulfide bonds and derivatization of free  SH groups 
were performed as follows. Peptide samples were reduced in vol- 
ume  to  1-2  I~1  by  vacuum centrifugation. Dithiothreitol  (30 
nmol in 5 I.L1 degassed Tris-buffer, 500 raM, pH 8) was added and 
the sample vortexed.  The solution was incubated under argon at 
37~  for 1 h. To the reduced peptides,  iodoacetamide (70 nmol 
in 5  ~1 H20  ) was added.  The mixture was vortexed and incu- 
bated in the dark,  under argon, at 37~  for  1 h.  The resulting 
derivative was analyzed without further treatment, by microcapil- 
lary  HPLC-electrospray  ionization/triple quadruple  mass spec- 
trometry (ESI-MS). 
Reverse-phase-HPLC  Separations.  Fractionation of the peptide 
extracts was performed on a separations system (model 130A; Ap- 
plied Biosystems, Foster City, CA). Peptide extracts were injected in 
100  ILl, 5% acetic  acid  solutions onto a narrow bore, reversed- 
phase column (RP-18 Spheri-5, 2.1 mm ￿  3 cm), and eluted at 
200 txl/minutes over 40 rain by a linear gradient of 0-60% aceto- 
nitrile (0.085% TFA) in 0.1% TFA. Fractions were manually col- 
lected into 0.65 Ixl siliconized tubes at 1-min intervals and imme- 
diately  frozen with dry ice.  Column effluent  was  monitored at 
214 nm. Care was taken to insure that each fractionation was car- 
ried out under as nearly identical conditions as possible.  HPLC 
fractions were concentrated by vacuum centrifugation to remove 
the acetonitrile and TFA before mass spectral analysis. 
Microcapillary RP-HPLC Separations.  Samples were introduced 
to the mass spectrometer by microcapillary  1KP-HPLC.  Samples 
were loaded hydrostatically  onto a 40-cm length of fused silica 
capillary (75 ~m inside diameter [i.d.], 180 Ixm outside diameter) 
packed  with  10-15  cm  of POROS  II/IKH  1KP  beads.  The 
amount of sample loaded was determined by measuring the vol- 
ume of solvent displaced from the column with a 1-5-~1 dispos- 
able pipette. Peptides were eluted by a 10-min gradient of 0-80% 
acetonitrile in 0.1 M acetic acid from a dual syringe pump (model 
140A;  Applied Biosystems).  A  precolumn split  of the  mobile 
phase  (flowing at 200  ~l/min) was used to obtain column flow 
rates  of 0.2-0.5  ~l/min. A  50  Ixm-i.d.  restriction capillary was 
used to control the back pressure of the system. 
ESI-MS.  Mass  spectra were recorded on a triple quadrupole 
mass spectrometer (model TSQ-70; Finnigan, San Jos6, CA) that 
had been upgraded with the electronics  and data system of TSQ- 
700, and the Finnigan API ion source.  A coaxial sheath liquid of 
3:1 methanol/0.1% acetic acid was employed. The spray was as- 
sisted by coaxial N 2 gas flow from sheath and auxiliary gas ports. 
Analytes were dissolved and transmitted to the first quadrupole by 
passage through a heated capillary and differentially pumped octa- 
pole lens region. 
Synthetic Peptides.  Synthetic  peptides  based  on  HIV  protein 
sequences were provided by the Cytel Corporation. Other pep- 
tides  were  synthesized  using  solid-phase  Fmoc  chemistry  on 
Wang resins  with  a  multiple peptide  synthesizer  (model AMS 
422; Gilson, Middletown, WI). 
RNA Extraction and Dot Blot Analysis.  Total  RNA  was  ex- 
tracted from 106 cells by the protocol supplied with the RNA Mi- 
cro-Isolation Kit (Stratagene  Inc., La Jolla,  CA).  Duplicate ali- 
quots of ~1  ktg of each sample were transferred to nitrocellulose 
membranes using a  dot  blot  apparatus  (Bio-Rad  Laboratories, 
Hercules,  CA).  Membranes were  incubated at  42~  with  10  ~' 
cpm/ml of either a 50-mer vinculin  oligonucleotide or a glyceral- 
dehyde phosphate  dehydrogenase  (GAPDH) probe, washed,  and 
then  exposed  to  either x-ray film or  the  imaging screen  of a 
Phosphorlmager 425 (Molecular Dynamics, Sunnyvale, CA). 
Flow Cytometry.  Cells were fixed with 4% paraformaldehyde 
in PBS for 5 min at room temperature (RT), and washed  three 
times with 50 mM NH4C1 in PBS and two times with cold PBS. 
Cells  were  permeabilized in  100  ~1  of 0.6%  n-octyl-[3-D-glu- 
copyranoside  for  5 min at  RT and washed  two  times  in PBS. 
Cells were then incubated with antivinculin  IgG1 mAb (Chemi- 
con International  Inc., Temecula, CA) for 45 min at RT, washed 
and stained with a PE-labeled anti-IgG1 antibody (Southern Bio- 
technologies,  Birmingham, AL). After further extensive washings, 
cells were  incubated with  either  anti-CD3-FITC IgG2a  mAb 
(OKT3-FITC; Ortho Diagnostics,  Raritan, NJ)  or anti-CD20- 
FITC IgG2b mAb (OKT20-FITC) for 30  rain at 4~  Finally, 
cells were  washed  and cell fluorescence  was  analyzed  with the 
FACScan  |  flow cytometer (Becton Dickinson & Co., Mountain 
View, CA). 
Generation Of CTL Lines.  PBMC (4-5 ￿  106) were incubated 
in 1KPMI containing 1% human AB serum for 90  min at 37~ 
and 5% CO2.  The nonadherent cells (PBL) were removed and 
the  adherent fraction was  pulsed with  100  ~g/ml of synthetic 
peptide overnight and used as a source  of APC. APC were then 
extensively washed  and incubated with  1.5  X  I(Y' responding 
PBL. After 5 d of culture, 10 U/ml rIL-2 (Proleukin, Emeryville, 
CA) was added and 2 d later, viable cells from each culture were 
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cultures  were  stimulated  further  with  peptide-pulsed  irradiated 
(3,000 rad) autologous PHA-T cell blasts  used as APC, expanded 
with rlL-2, and tested for their ability to recognize endogenously 
synthesized  antigen  in  infected  target  cells.  PBL-derived  from 
random-selected healthy subjects were primed in vitro by weekly 
restimulation with autologous peptide-pulsed APC and expanded 
with rlL2.  After five to six rounds  of restimulation,  the cultures 
were analyzed for peptide-specific CTL activity and those found 
to  be  peptide-specific  were  used  for  the  generation  of  CTL 
clones. 
Generation of CTL Clones.  T  cells  clones  were  isolated  and 
maintained as previously described (11).  Briefly, peptide-specific 
CTL lines were cloned by limiting dilution at 0.3 cells/well into 
96-well  U-bottom  plates  in  the  presence  of 0.5  I~g/ml  PHA 
(PHA-P; Wetlcome, Beckenham, UK), 50 U/ml rlL-2, and irra- 
diated, allogeneic feeder cells. After 2-3 wk, cell growth was de- 
tected using an inverted microscope and  growing cultures were 
tested  for their  ability to  kill peptide-pulsed  SlCr-labeled target 
cells. Peptide-specific CD8 + CTL clones were then expanded in 
rIL-2-containing medium and maintained in culture with 2-wk 
cycles of restimulation with PHA and allogeneic APC. 
Results  and  Discussion 
Given the prevalent expression of the class I  allele HLA- 
A2.1  ("-~46%  among  Caucasians)  (12),  we  undertook  a  sub- 
tractive analysis of peptides extracted from HLA-A2.1 mol- 
ecules purified from a B  cell line that was either uninfected or 
infected with HIViim in vitro. We  carried  out our experi- 
ments using B  cells since the peptides presented by HLA-A2.1 
on B-lymphoblastoid  cells have been previously character- 
ized  (10).  Although  B  cells  do  not  represent  the  primary 
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Figure 1.  Ion chromatograms  of peptides 
extracted from HLA-A2.1 molecules. HLA- 
A2.1 molecules  were purified  from lysates 
of AA2 and AA2-IIIB cells by immunoaf- 
finity  chromatography  following described 
procedures  (10). Shown is  HPLC  fraction 
15 of uninfected  (A) and HIV-infected (B) 
AA2 cells, with the mass spectrum  (C) of a 
peptide  unique to infected  cells. The frac- 
tions containing  peptides from three prepa- 
rations  were  pooled  and  concentrated  by 
vacuum centrifugation.  Peptides  were frac- 
tionated  by HPLC on a 2.1  nma  ￿  3  cm 
C18 colunm (ABI). A 40-min binary gradi- 
ent at 200  Ixl/min of 0--60% solvent B was 
used  to  elute  the  peptides,  with  fractions 
collected  at 1-min intervals. Solvent A was 
H20 and 0.1% TFA; solvent B was 60% ac- 
etonitrile,  30%  HzO, 0.085% TFA.  Frac- 
tions were concentrated  and aliquots corre- 
sponding  to  1.5  ￿  109  cells analyzed  by 
capillary  LC-MS  as  described  previously 
(10). A  spectrum  covering the  mass range 
300-1,400  was acquired  every 1.5 s. Total 
ion currents were obtained by summing the 
signal from  every mass in  each  spectrum. 
The extracted ion currents represent the sig- 
nal in each spectrum due to ions of a partic- 
ular m/z. 
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both in vitro (13,  14) and in vivo (15). Peptides were ana- 
lyzed  using  the  technique  of capillary HPLC  coupled  with 
ESI-TMS (10). 
Peptides  associated with HLA-A2.1  molecules were pu- 
rified from both  control  and  100% HIV-l-infected  clonal 
populations of AA2 cells. The extracted peptides were frac- 
tionated by RP-HPLC.  Aliquots  of each fraction were re- 
chromatographed by capillary RP-HPLC,  and the resultant 
fractions were then directly analyzed by ESI-TMS.  At ev- 
ery stage of the procedure,  samples from control and HIV- 
infected  cells were  treated identically.  The mass spectra of 
each  HPLC  fraction  from  infected  cells  were  compared, 
peptide by peptide,  to the mass spectra of the  correspond- 
ing HPLC fraction from control cells. Where peptides ap- 
peared  to  be  unique  to  either  sample,  adjacent  fractions 
were  also  examined  to determine  whether  or not  the  dis- 
parity was simply due to a shift in retention time. 
An  example  of this  approach  is illustrated  in  Fig.  1,  in 
which  peptides from fraction  15  of control  (Fig.  1 A)  and 
HIV-infected (Fig.  1 B)  cells were compared.  The bottom 
panels of Fig.  1, A  and B show the total ion chromatograms 
for each run;  mass spectra were recorded  every 1.5  s.  The 
upper panels represent the elution ofpeptides with particu- 
lar charge/mass  (m/z)  values.  Virtually all of the  abundant 
peptide  ions  identified  from the  control  sample were  also 
present  in  the  sample  from  HIV-infected  cells.  Peptides 
with m/z 458 and 481  are present in both samples in simi- 
lar proportions and were used as markers. The peptide with 
m/z 463, which elutes in the interval between these mark- 
ers,  is present  in  only the  sample from infected  cells.  The 
summed mass spectra (Fig,  1 C) reveal that this unique pep- 
tide is doubly charged and has a nominal molecular mass of 
925 daltons. 
Application  of this  method  revealed three  peptides  that 
appeared  only  in  the  samples  derived  from  HIV-infected 
cells (Table 1). The sequences of these peptides were deter- 
mined by collision-activated dissociation (CAD) on the tri- 
ple quadrupole mass spectrometer. Each peptide is nine res- 
idues long and exhibits the HLA-A2.1-binding  motif (10). 
Synthetic  versions  of peptides  1 and 2  displayed moderate 
affinity for HLA-A2.1  in an in vitro peptide--binding assay 
(16)  (Table 1). Protein sequence databases were searched to 
identify the protein precursors of these peptides.  The three 
peptide sequences were found to occur within a single cel- 
lular protein, human vinculin.  Vinculin,  a cytoskeletal pro- 
tein,  is an  essential component  of cell-extracellular  matrix 
adhesions involving integrins  (focal adhesions)  and cell-cell 
adhesions involving cadherins (adherens junctions)  (17). Pep- 
tides  1,  2, and 3  were redesignated  according to their cor- 
responding positions in the vinculin  protein sequence  (18) 
as  Vine(359_367), Vinc(823_831)  ,  and  Vinc(983_991), respectively. 
The third peptide is unusual  in that it contains  a modified 
residue  at position  3.  Reduction  and  carboxyamidation  of 
this  peptide  results  in a  loss of 45  daltons,  consistent  with 
the  release  of an unknown  group with  a mass of 102  dal- 
tons,  followed by addition  of the 57-dalton  accompanying 
carboxyamidation of one Cys, suggesting that this residue is 
Cys modified through  a  disulfide linkage.  It is not known 
whether  this  modification  preceded  antigen  processing  or 
was introduced  during peptide  extraction  and purification. 
The third peptide exactly matches residues 983-991  ofvin- 
culin,  providing that Cys is assigned to peptide position  3, 
corresponding to Cys985 in the published sequence  (18), in 
accord with our interpretation  of the CAD data. 
Surprisingly, despite readily demonstrable synthesis of HIV 
proteins  in  AA2-IIIB  cells,  our  analyses  failed  to  identify 
HIV-derived  peptides  in  eluates  prepared  from  infected 
cells,  either  by  subtractive  analysis  or  through  a  direct 
search aided by a large panel of synthetic HIV peptides se- 
lected for their ability to bind to HLA-A2.1.  Peptides  that 
could  be  derived  from  HIV  proteins  in  regions  that  are 
conserved  among many viral strains  were  synthesized  aaad 
tested for HLA-A2.1  binding using the  quantitative,  solu- 
Table 1.  Peptides  Extraaed from HLA-A2.1 Molecules Uniquely Associated with HIV-infected AA2 cells (AA2-II1B) 
HLA-A2.1 
[M+H]  Yield (fmol)  Pepfide  Vinculin  binding 
Peptide  (m/z)  AA2-II1B  sequence  sequence  ICso 
1  914  140 
2  925  380 
3  1,160  200 
nM 
GXDVXTAKV  GLDVLTAKV (358-366)  132 
RXXGAVAKV  RILGAVAKV (823-831)  91 
QVZERXPTX  QVCERIPTI  (983-991)  ND 
Aliquots corresponding to 1.5 ￿  109 cells were analyzed by capillary HPLC-ES1-MS.  Yields are based on comparisons with a peptide standard. No 
discrete peaks corresponding to peptides 1-3 were discerned in AA2 (uninfected) eluates. Unresolved, low abundance peptides in these complex 
mixtures produced background signals of 1-10 fmol, establishing our threshold of detection. Amino acids are shown in single letter code: A, Ala; C, 
Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; Y, Tyr. 
The letter Z represents Cys modified by an unknown group with a molecular mass of 102. X is used to designate either Leu or lie, which are not dis- 
tinguishable by tandem MS. All three peptides were observed as the doubly charged ions [M  +  2H] 2+ at one half of the m/z values shown. Also 
shown are the concentrations  of peptide  (IC50 values), which produced  half-maximal inhibition  of binding of a radiolabeled standard peptide to 
HLA-A2.1 molecules in an in vitro-binding assay. 
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viously  described  epitopes,  were  identified  that  bound  to 
HLA-A2.1  with  various  affinities;  infected  B  cell  class  I 
preparations  were  analyzed  for  the  presence  of  the  36 
strongest  binding  candidates.  Searches  were  based  on  the 
retention  times  of the  synthetic  peptides.  Each  synthetic 
peptide  was screened by ESI-TMS to verify its  molecular 
mass and to determine its characteristic charge state. An ali- 
quot  of each synthetic  peptide  was doped into  a  prepara- 
tion of B  cell peptides,  and the resulting mixture was frac- 
tionated by RP-HPLC. Capillary HPLC-ESI-TMS was used 
to  screen  each  fraction,  and  the  synthetic  peptides  were 
identified  on the basis  of mass,  charge  state,  and their  ab- 
sence  in preparations  that had not been doped.  A  hst was 
thus  compiled  that  located  the  HPLC  fraction  in  which 
each HIV peptide was expected to be found, and the HPLC 
fractions  of infected  cell  peptides  were  searched  accord- 
ingly.  For example,  a peptide  with  a  molecular weight  of 
1,012 was found in HPLC fraction 17 in the doped sample; 
analysis of fraction 17 of the HIV-infected sample revealed 
no corresponding peptide with the correct mass and charge 
state.  The neighboring fractions were also analyzed for the 
peptide in case the HPLC separations were not completely 
congruent.  No match was found in  these  fractions  either. 
Several  possible  matches  were  generated  by  this  method, 
but in  each  case  the  CAD  spectrum  of the  candidate  did 
not match that of the synthetic peptide. When searches for 
each  of the  36  peptides  proved  unsuccessful,  additional 
searches were initiated  for the expanded set of peptides  on 
the  basis  of molecular  mass  alone,  but  again  no  positive 
matches were found for these peptides. One obvious expla- 
nation for this result is that HLA-A2.1-associated HIV pep- 
tides are ineffciently processed and presented, at least in AA2- 
IIIB cells,  and  as  a  consequence  are  difficult  to  detect by 
ESI-TMS.  The  possibility  remains,  however,  that  the  use 
of different  conditions  or cells might allow direct identifi- 
cation of HIV-derived peptides presented by infected cells. 
The identification of vinculin-derived peptides uniquely 
associated  with  HLA-A2.1  molecules  from  infected  cells 
suggested that vinculin might be  overexpressed  as  a  result 
of  viral infection. To test this hypothesis, we performed dot 
blots  (Fig.  2  A)  with  a  vincuhn  ohgonucleotide probe  on 
total  cellular  P,.NA  from AA2  and  AA2-IIIB cells.  In re- 
peated  experiments,  strong  signals  were  observed  for in- 
fected cells,  whereas  vinculin mRNA  expression was faint 
to undetectable  in  uninfected  cells.  Northern blot analysis 
confirmed that the signal observed for AA2-IIIB cells arose 
from a  single  intense  band corresponding to  the  expected 
size  of vinculin  mRNA  (data  not  shown).  [35S]Cysteine 
metabohc labeling of uninfected and infected cells followed 
by immunoprecipitation  with vincuhn-specific mAbs con- 
firmed  overexpression  of vinculin  at  the  protein  level  as 
well  (data  not  shown).  Dot  blot  analysis  was  additionally 
performed for total RNA  from PBMC from HLA-A2.1+, 
HIV-l-infected  subjects  in  the  symptomatic  phase  of 
AIDS,  using PBMC  from HLA-A2.1 +  healthy subjects  as 
controls.  Elevated  vinculin  levels  were  observed  for each 
HIV  +  individual  tested,  indicating  that the vinculin  over- 
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Figure 2.  Expression of vinculin by dot blot analysis of mR.NA levels 
(A and B) and by immunofluorescence  labeling followed by flow cytom- 
etry (C). (A) Autoradiogram showing vincuhn mP.NA levels in HIVnm- 
infected AA2 cells and PBMC from HIV  + patients (A, B, and C) com- 
pared to uninfected AA2 cells and PBMC from an HIV- donor (donor 3). 
(B)  Vinculin mlq.NA expression quantitated with  a  Phosphorlmager. 
Pixel values were normalized to GAPDH values and are plotted for PBL 
from HIV- donors (PBL 1, 2, and 3) and adherent (Mo) and nonadherent 
(PBL) fractions of PBMC from HIV  + patients A, B, and C.  (C) Two- 
color staining of vincuhn and either CD20  + B or CD3 + T lymphocytes 
from a representative HIV-1 + patient. The ordinate represents intracyto- 
solic vinculin staining and the abscissa represents either membrane CD20 
or CD3 expression. Intracellular vinculin expression was detectable in B 
and T cells of 8 out of 10 HIV-infected patients tested, but in 0 out of 10 
healthy individuals. 
expression  observed  in  AA2  cells  upon  in  vitro  infection 
reflects  a  more  general  phenomenon  occurring  in  vivo. 
When PBMC were separated into adherent and nonadher- 
ent (PBL) fractions and similarly analyzed, increased vincu- 
hn  expression  was  observed  mainly  in  the  PBL  fraction, 
comprised  mostly  of T  and  B  lymphocytes  (Fig.  2  B). 
Moreover,  flow cytometric analysis by two-color staining 
of PBL  from  HIV-l-infected  subjects  confirmed  the  in- 
creased expression of endocellular vincuhn in a fraction of 
both the B  and T  cell populations (Fig. 2  C). 
To determine whether vincuhn-derived peptides are im- 
munogenic for CTL responses, two different approaches were 
followed. In the first approach, we sought to ehcit CTL re- 
sponses  in  PBL  derived  from HIV-1 +  patients  or healthy 
donors  after  a  single  in vitro  stimulation  with  autologous q~ 
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Figure 3.  Vincuhn-specific  CTL response 
in patients with HIV infection. PBL derived 
from  HLA-A2.1  §  (A) or HLA-A2.1-  (B) 
HIV + patients, or from healthy subjects (C), 
were  incubated  with  autologous adherent 
cells that previously were pulsed with  100 
I.~g/ml of either Vinc(3sg_3r  )  or  Vinc(823_831) 
peptides. After  5  d,  10  U/ml  rlL-2  was 
added and after a further 2 d, the cultures 
generated from HLA-A2.1  + PBL were in- 
dividually  tested  for  specific cytotoxicity 
against peptide-pulsed  (10  lag/ml)  or un- 
treated HLA-A2.1  + cell lines  JY and AA2 at 
an E/T ratio of 50:1. Cultures derived from 
HLA-A2.1- individuals were tested against 
autologous  PHA-activated  T  cell  blasts. 
Values for percent specific lysis reflect the 
mean  of triplicate  determinations.  HLA- 
A2+/HIV  + patients (A) belonged to either 
the  A1  group  (patients  1-18), A2  group 
(patients 19-23), B2 group (patients 24 and 
25), or to the  C3  group  (patients 26 and 
27), according to the  Centers for Disease 
Control classification  scheme. All HLA-A2- 
patients  (B)  belonged  to  the  A1  group. 
Healthy subjects (C) were negative for HIV, 
heapatitis  B virus, and hepatitis C virus sero- 
logical markers. 
peptide-pulsed adherent  monocytes  (APC)  (Fig.  3).  CTL 
that  lysed target  cells pulsed with  vinculin peptides were 
elicited  in  vitro  after  a  single  stimulation  from  PBL  of 
HLA-A2.1 + patients, but not from PBL of HLA-A2.1- pa- 
tients or HLA-A2.1 + normal donors, suggesting that CTL 
from  HLA-A2.1 +  patients were  vincuhn  primed in  vivo. 
Moreover,  6  out  of  11  long-term  CTL  lines,  expanded 
from  randomly selected vinculin-specific cultures  of HIV 
patients  by  a  second  restimulation  with  peptide-pulsed 
APC  and  IL-2,  killed  not  only  peptide-sensitized target 
cells in a class I-restricted manner but also HIV-l-infected 
AA2 cells (Fig. 4 A). In the second approach, a protocol for 
in vitro priming of peptide-specific CTL,  generated from 
PBL  of healthy  donors,  was  developed.  After five  to  six 
rounds  of  stimulation  with  autologous  peptide-pulsed 
APC,  a  peptide-specific CTL  response  was  detectable  in 
cultures from four out of nine healthy subjects tested, indi- 
cating that vinculin-specific CTL  precusors are present in 
the normal T  cell repertoire. As evident from a typical ex- 
periment shown in Fig. 4 B, three representative Vinc(359_367)- 
specific  CTL  clones,  generated  from  an  in  vitro  peptide- 
primed T  cell line, lysed both peptide-pulsed HLA-A2.1 + 
target cells and AA2-IIIB cells. Jurkat cells expressing HLA 
A2.1,  although  productively infected with  HIV-lmB,  did 
not  overexpress  vinculin  as  result  of viral  infection  and 
were not susceptible to lysis by vincuhn-specific  CTL (Fig. 
4  /3).  These  results,  together with the lack of any obvious 
homology between the vinculin-derived peptides described 
here and HIV-derived sequences, suggest that the self-reactive 
CTL observed among HIV + subjects arise as a consequence 
of vinculin overexpression and not through  HIV/vinculin 
cross-reactivity. 
The above findings provide in vivo correlates of our ob- 
servations of AA2 cells infected with HIV in vitro.  Over- 
expression  of vinculin  is  directly  observed  in  PBL  from 
HIV +  patients.  Additionally, the  finding of primed  CTL, 
specific  for  the  same  vinculin  peptides  recovered  from 
AA2-IIIB cells,  in  >50%  of the  HLA-A2.1 +,  HIV +  pa- 
tients  studied,  strongly  implies  that  HLA-A2.1-mediated 
presentation  of vinculin-derived peptides  occurs  in  vivo. 
Overexpression of cellular proteins upon HIV infection has 
been  described  previously  by  others  (19-21)  who  have 
shown that dysregulated expression of cellular proteins may 
be driven by Tat-mediated transactivation of cellular pro- 
moters.  Atypical  (ectopic)  cellular protein  expression  re- 
sulting in the induction of CTL has also been observed in a 
subpopulation of malignant melanoma patients (22, 23). 
Recently, it has been demonstrated that presentation of 
self-antigens is induced by the HIV gp120-driven internal- 
ization of surface CD4 molecules, leading to enhanced CD4 
processing and presentation of MHC  class II/CD4 epitopes 
to  autoreactive  CD4-specific  T  helper  cells  (24).  As  de- 
scribed here, the creation of apparently novel class I-vincu- 
lin peptide complexes serves to trigger autoreactive CTL in 
a  number  of HIV +  individuals. These  results indicate that 
HIV infection upregulates the synthesis of vinculin in host 
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Figure  4.  CTL  raised against 
synthetic vinculin  peptides recog- 
nize  naturally processed peptides 
presented by HIV-infected  cells, 
as  well  as  peptide-pulsed  target 
cells. (A) CTL derived from PBL 
of  HIV  +  patients,  selected  for 
their  capacity  to  lyse peptide- 
pulsed target cells, were expanded 
by a further  restimulation  with 
peptide-pulsed  autologous  APC 
and  IL-2.  (a-c) Representative 
Vinc(359.367)-  or (d-f) Vinc(823_831)- 
specific  CTL  lines  were  tested 
for  their  capacity  to  lyse AA2 
cells pulsed with either Vine(359_367) 
(O) or Vinc(s23-s31)  (O) and in the 
presence of anfi-HLA-ABC mAb 
W6/32  (A)  or  a  pool  of anti- 
HLA class-II mAbs (A).  Shown 
also are the results obtained using 
HIVmB-infected  (11) or uninfected 
([])  AA2  cells  as  targets. (B) 
Three representative Vinc(359_367)- 
specific CD8 + T-cell clones (a-c) 
generated  from in vitro-primed 
CTL isolated from healthy sub- 
jects,  tested  for  their  ability  to 
lyse  Vinc(359_367)-pulsed HLA- 
A2  § JY (Q) or HLA-A2- HHK 
(O) target cells, HIViuB-infected 
(11) or uninfected (U]) AA2 cells, 
and  HIV-l.lD-infected  (A)  or 
uninfected  (~)  Jurkat  HLA- 
A2.1 § cells. 
cells, allowing the  generation of vinculin-derived epitopes 
in cytosolic processing compartments,  and the  priming of 
autoreactive  vinculin-specific  CTL  responses.  Moreover, 
the  finding that  primary  vincuhn-specific CTL  responses 
can be generated in vitro from PBL of healthy subjects, af- 
ter  repeated  stimulations  with  vinculin  peptide--pulsed 
APC,  suggests  that  these  self-reactive  CTL  are  present  in 
the peripheral repertoire of normal individuals and become 
activated upon  HIV  infection. Self-reactivity in general is 
currently understood to  arise by several  mechanisms  (25). 
In addition to  a  potentially important role  in HIV patho- 
genesis, the present results obtained for vinculin provide, to 
our knowledge, the first demonstration of virus-dependent 
overexpression  of a  cellular protein  implicated in  the  in- 
duction of self-reactive CTL in infected individuals. 
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